argenx (ARGX): next trial readout expected around 2026-09-30
Trials that could report in the next 12 months: 10BiopharmaCTG
Catalyst timeline
Dates are estimated from each trial's registered completion date — none are FDA decision dates. Counts trials that fit our shared poll budget, not everything ARGX is running — see methodology.
- 2026-09-30in 6wA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
- 2026-10-01in 6wA Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
- 2026-12-31in 19wA Study to Assess the Safety of ARGX-124 in Healthy Volunteers
- 2027-04-30in 36wA Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
- 2027-10-07in 59wA Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
- 2028-03-07in 81wADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- 2028-07-28in 101wA Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
- 2029-01-20in 126wA Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults
- 2029-05-28in 145wA Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
- 2029-09-30in 163wA Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
Pipeline
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| A Clinical Trial to Investigate the Long-term Safety and Tolerability,… | Phase 2 | Active Not Recruitingenrolled, still running | 2029-09-30 | NCT05405361 |
| A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics… | Phase 2 | Recruitingstill enrolling patients | 2029-05-28 | NCT07287982 |
| A Study to Learn About How Well the Medicine Efgartigimod Works to Tre… | Phase 2 | Not Yet Recruitingnot open yet | 2029-01-20 | NCT07583641 |
| A Study to Assess Efficacy and Safety of Efgartigimod in Adults With S… | Phase 2 | Not Yet Recruitingnot open yet | 2028-07-28 | NCT07760818 |
| ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-o… | Phase 2 | Recruitingstill enrolling patients | 2028-03-07 | NCT07284420 |
| A Study to Assess the Efficacy and Safety of Empasiprubart in Adults W… | Phase 3 | Recruitingstill enrolling patients | 2027-10-07 | NCT07091630 |
| A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous … | Phase 2 | Active Not Recruitingenrolled, still running | 2027-04-30 | NCT04280718 |
| A Study to Assess the Safety of ARGX-124 in Healthy Volunteers | Phase 1 | Recruitingstill enrolling patients | 2026-12-31 | NCT07377396 |
+ 16 more tracked trials
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH… | Phase 3 | Active Not Recruitingenrolled, still running | 2026-10-01 | NCT04812925 |
| A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18… | Phase 2 | Recruitingstill enrolling patients | 2026-09-30 | NCT06392386 |
| A Study of Efgartigimod IV in Participants From 12 Years to Less Than … | Phase 2 | Recruitingstill enrolling patients | NCT07194850 | |
| A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in A… | Phase 3 | Recruitingstill enrolling patients | NCT07570316 | |
| A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in A… | Phase 3 | Recruitingstill enrolling patients | NCT07596849 | |
| Evaluating Long-term Safety of Efgartigimod Administered Intravenously… | Phase 2 | Enrolling By Invitation | NCT05374590 | |
| ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability … | Phase 2 | Recruitingstill enrolling patients | NCT07673627 | |
| A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous … | Phase 3 | Enrolling By Invitation | NCT05979441 | |
| Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgar… | Phase 2 | Recruitingstill enrolling patients | NCT04833894 | |
| A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults Wit… | Phase 2 | Active Not Recruitingenrolled, still running | NCT06284954 | |
| A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 S… | Phase 2 | Active Not Recruitingenrolled, still running | NCT06503731 | |
| A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult … | Phase 3 | Recruitingstill enrolling patients | NCT06544499 | |
| A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in A… | Phase 2 | Recruitingstill enrolling patients | NCT06655155 | |
| A Study of the Efficacy and Safety of Efgartigimod in Patients With Pr… | Phase 3 | Active Not Recruitingenrolled, still running | NCT06684847 | |
| A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg… | Phase 3 | Active Not Recruitingenrolled, still running | NCT06742190 | |
| A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in … | Phase 3 | Recruitingstill enrolling patients | NCT06920004 |
Status-change history
Every ClinicalTrials.gov change recorded for ARGX's trials — a running history no other tracker shows.
No status changes detected yet for this ticker.
Frequently asked
When is ARGX's next PDUFA date?
No disclosed PDUFA date is currently tracked for this ticker.
What phase is ARGX's lead program in?
Phase 3 — recruiting.
Where does this data come from?
ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.